Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for rheumatoid arthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoidarthritis 3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) are standard treatment for hyperlipidaemia. In addition to lipid-lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease
A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoidarthritis and a prior malignancy To explore the risk of new and recurrent cancer in adult RA patients with prior malignancy and subsequently exposed to biologic therapies.Separate searches were performed of PubMed, EMBASE and Cochrane Library and conference proceedings for observational studies reporting cancer incidence or recurrence in patients with RA and prior malignancy treated
Trends in all-cause and cardiovascular mortality in patients with incident rheumatoidarthritis: a 20-year follow-up matched case-cohort study To examine all-cause and cardiovascular disease (CVD) mortality in consecutive cohorts of patients with incident RA, compared with population comparators.The Oslo RA register inclusion criteria were diagnosis of RA (1987 ACR criteria) and residency in Oslo. Patients with disease onset 1994-2008 and 10 matched comparators for each case were linked
Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoidarthritis with COPD: a real-world population study Abatacept, a biologic DMARD, was associated with respiratory adverse events in a small subgroup of RA patients with chronic obstructive pulmonary disease (COPD) in a trial. Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. We assessed the risk of adverse respiratory events
Remission vs low disease activity: function, quality of life and structural outcomes in the Early RheumatoidArthritis Study and Network To examine associations between function, quality of life and structural outcomes in patients achieving remission vs low disease activity in early RA.Demographic, clinical and radiographic variables were collected at baseline and then annually from the Early RheumatoidArthritis Study (ERAS) and Early RheumatoidArthritis Network (ERAN) inception cohorts
Upadacitinib (Rinvoq) - rheumatoidarthritis CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211675Orig1s000 CLINICAL REVIEW(S) Clinical Review Keith M Hull, MD, PhD NDA 211675 RINVOQ (upadacitinib) CLINICAL REVIEW Application Type NDA Application Number(s) 211675 Priority or Standard Priority Submit Date(s) 18 Dec 2018 Received Date(s) 18 Dec 2018 PDUFA Goal Date 18 Aug 2019 Division/Office Division of Pulmonary, Allergy and Rheumatology Products Reviewer Name(s) Keith M Hull, MD (...) , PhD Review Completion Date 17 May 2019 Established/Proper Name Upadacitinib (Proposed) Trade Name RINVOQ Applicant AbbVie Inc Dosage Form(s) 15 mg extended release tablets Applicant Proposed Dosing Regimen(s) 15 mg orally administered QD Applicant Proposed Indication(s)/Population(s) Recommendation on Regulatory Action Approval Recommended Indication(s)/Population(s) (if applicable) Treatment of adults with moderately to severely active rheumatoidarthritis who had an inadequate response
Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of RheumatoidArthritis Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of RheumatoidArthritis | CADTH.ca Find the information you need Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of RheumatoidArthritis Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of RheumatoidArthritis Last (...) updated: March 26, 2019 Project Number: RC1087-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of triple conventional synthetic disease-modifying anti-rheumatic drugs compared with other pharmacologic options for the management of rheumatoidarthritis? Key Message Two relevant publications comprising cost-effectiveness analyses were identified; one involved patients with rheumatoidarthritis (RA) that could
Upadacitinib (TBC) - Arthritis, Rheumatoid upadacitinib | CADTH.ca Find the information you need upadacitinib upadacitinib Last Updated: October 4, 2019 Result type: Reports Project Number: SR0614-000 Product Line: Generic Name: upadacitinib Brand Name: TBC Manufacturer: AbbVie Indications: Arthritis, Rheumatoid Manufacturer Requested Reimbursement Criteria 1 : Upadacitinib to be listed for the treatment of moderate to severe active rheumatoidarthritis in adult patients who have responded (...) recommendation, if applicable. Key Milestones 2 Call for patient input posted May 31, 2019 Patient group input closed July 22, 2019 Clarification: - Patient input submission received from the Arthritis Consumer Experts, Canadian Arthritis Patient Alliance (CAPA) & The Arthritis Society Patient input summary sent for review to patient input groups July 30, 2019 Patient group comments on input summary closed August 07, 2019 Clarification: - Patient input summary feedback received Submission received July 04
Olumiant - baricitinib - Arthritis, Rheumatoid baricitinib | CADTH.ca Find the information you need baricitinib baricitinib Last Updated: September 12, 2019 Result type: Reports Project Number: SR0597-000 Product Line: Generic Name: baricitinib Brand Name: Olumiant Manufacturer: Eli Lilly Canada Inc. Indications: Arthritis, Rheumatoid Manufacturer Requested Reimbursement Criteria 1 : In combination with methotrexate (MTX), indicated for reducing the signs and symptoms of moderate to severe (...) rheumatoidarthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs).Olumiant may be used as monotherapy in cases of intolerance to MTX. Submission Type: New Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: August 2, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do
Anti-interleukin-1 treatment in patients with rheumatoidarthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoidarthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory (...) haemoglobin (HbA1c%) (EudraCT: 2012-005370-62 ClinicalTrial.gov: NCT02236481). In total, 41 participants with RA and T2D were randomised, and 39 eligible participants were treated (age 62.72 ± 9.97 years, 74.4% female sex). The majority of participants had seropositive RA disease (rheumatoid factor and/or anticyclic citrullinated peptide antibody [ACPA] 70.2%) with active disease (Disease Activity Score-28 [DAS28]: 5.54 ± 1.03; C-reactive protein 11.84 ± 9.67 mg/L, respectively). All participants had T2D
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoidarthritis 1 Translation of Chapters 1 to 6 of the final report A16-70 Biotechnologisch hergestellte Wirkstoffe bei rheumatoiderArthritis (Version 1.0; Status: 23 July 2019 [German original], 16 September 2019 [English translation]). Please note: This document is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract IQWiG Reports – Commission No. A16-70 Biologics for rheumatoidarthritis 1 Extract of final report A16-70 Version 1.0 Biologics for rheumatoidarthritis 23 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Biologics for rheumatoidarthritis Commissioning agency: Federal Joint Committee Commission awarded on: 24 November 2016 Internal Commission No.: A16-70 Address
Rituximab as Maintenance Treatment in RheumatoidArthritis Rituximab as Maintenance Treatment in RheumatoidArthritis | CADTH.ca Find the information you need Rituximab as Maintenance Treatment in RheumatoidArthritis Rituximab as Maintenance Treatment in RheumatoidArthritis Last updated: March 29, 2019 Project Number: HO0002-000 - HE0021-000 Product Line: Technology Review Result type: Report This project reviewed the evidence on the administration of repeated courses of rituximab
Tai Chi for rheumatoidarthritis. Rheumatoidarthritis (RA) is a chronic, systemic, inflammatory, autoimmune disease that results in joint deformity and immobility of the musculoskeletal system. The major goals of treatment are to relieve pain, reduce inflammation, slow down or stop joint damage, prevent disability, and preserve or improve the person's sense of well-being and ability to function. Tai Chi, interchangeably known as Tai Chi Chuan, is an ancient Chinese health-promoting martial art (...) form that has been recognized in China as an effective arthritis therapy for centuries. This is an update of a review published in 2004.To assess the benefits and harms of Tai Chi as a treatment for people with rheumatoidarthritis (RA).We updated the search of CENTRAL, MEDLINE, Embase, and clinical trial registries from 2002 to September 2018.We selected randomized controlled trials and controlled clinical trials examining the benefits (ACR improvement criteria or pain, disease progression
Upadacitinib Versus Placebo or Adalimumab in Patients With RheumatoidArthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoidarthritis (RA) who have experienced an inadequate response to methotrexate (MTX).In total, 1,629 RA
Efficacy of Atlantoaxial Joint Glucocorticoid Injection in Patients with RheumatoidArthritis: A Randomized Trial The atlantoaxial joint (AAJ) plays a pivotal role in the cervical spine motion. Unfortunately, it is the most common cervical spine joint that is affected in patients with rheumatoidarthritis. Inflammation of the AAJ results in neck disability, nerve root compression, and finally spinal cord compression.We aim to evaluate the efficacy of intraarticular triamcinolone injection (...) of the AAJ on neck pain and disability.A prospective randomized, controlled clinical trial.An interventional pain unit in a tertiary center at a university hospital in Egypt.Sixty patients with rheumatoidarthritis complaining of AAJ arthritis were randomized into 2 groups. Group AAJI (n = 30) received AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of 20 mg of triamcinolone, in addition to oral placebo tablets (2 tablets every 8 hours for one week). Group SS (n = 30